Accuracy of Infection Biomarkers in the Investigation of Patients With Suspected Acute Pyelonephritis

CompletedOBSERVATIONAL
Enrollment

229

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

February 28, 2022

Study Completion Date

June 1, 2022

Conditions
Acute Pyelonephritis
Interventions
DIAGNOSTIC_TEST

Biomarkers for acute pyelonephritis

"Blood samples will be collected by a medical laboratory technologist and transferred to the local laboratory for analysis of CRP, PCT and suPAR. Laboratory staff will be blinded to participant diagnosis and outcome. CRP and PCT results will be available to the treating physician, but the suPAR result will not be available.~* Diagnostic test of CRP. CRP will be measured using an immunoturbidimetric assay (Tina-quant®, Roche) on Roche/Hitachi Cobas© systems.~* Diagnostic test of PCT: Plasma PCT will be quantified by an automated sandwich immunoassay ECLIA (Elecsys®, BRAHMS PCT-analyses) on Cobas© within two hours from collection according to standard procedure.~* Diagnostic test of suPAR: Plasma suPAR will be quantified by using the commercial available suPARnostic© Tubilatex assay reagents (ViroGates, Denmark) on Cobas© as previously validated (35). Separated plasma is kept refrigerated and analysed for suPAR within 48 hours after collection."

Trial Locations (1)

Unknown

Hospital of Southern Jutland, Aabenraa

All Listed Sponsors
lead

University of Southern Denmark

OTHER

NCT04686318 - Accuracy of Infection Biomarkers in the Investigation of Patients With Suspected Acute Pyelonephritis | Biotech Hunter | Biotech Hunter